Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol

The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Ne...

Full description

Saved in:
Bibliographic Details
Main Authors: Stoop, Thomas F. (Author) , Seelen, L. W. F. (Author) , Land, F. R. van 't (Author) , Hout, A. C. van der (Author) , Scheepens, J. C. M. (Author) , Ali, M. (Author) , Stiggelbout, A. M. (Author) , Kolk, B. M. van der (Author) , Bonsing, B. A. (Author) , Lips, D. J. (Author) , Groot, D. J. A. de (Author) , Veldhuisen, E. van (Author) , Kerver, E. D. (Author) , Manusama, E. R. (Author) , Daams, F. (Author) , Kazemier, G. (Author) , Cirkel, G. A. (Author) , Tienhoven, G. van (Author) , Patijn, G. A. (Author) , Lelieveld-Rier, H. N. (Author) , de Hingh, I. H. (Author) , van Hellemond, I. E. G. (Author) , Wijsman, J. H. (Author) , Erdmann, J. I. (Author) , Mieog, J. S. D. (Author) , Vos-Geelen, J. de (Author) , Groot, J. W. B. de (Author) , Lutchman, K. R. D. (Author) , Mekenkamp, L. J. (Author) , Kranenburg, L. W. (Author) , Beuk, L. P. M. (Author) , Nijkamp, M. W. (Author) , den Dulk, M. (Author) , Polée, M. B. (Author) , Homs, M. Y. V. (Author) , Wumkes, M. L. (Author) , Stommel, M. W. J. (Author) , Busch, O. R. (Author) , Wilde, R. F. de (Author) , Theijse, R. T. (Author) , Luelmo, S. A. C. (Author) , Festen, S. (Author) , Bollen, T. L. (Author) , Neumann, U. P. (Author) , Meijer, V. E. de (Author) , Draaisma, W. A. (Author) , Groot Koerkamp, B. (Author) , Molenaar, I. Q. (Author) , Wolfgang, C. L. (Author) , Del Chiaro, M. (Author) , Katz, M. G. H. (Author) , Hackert, Thilo (Author) , Rietjens, J. A. C. (Author) , Wilmink, J. W. (Author) , Santvoort, H. C. van (Author) , Eijck, C. H. J. van (Author) , Besselink, M. G. (Author) , Bruynzeel, A. (Author) , Vlijm, A. (Author) , Asseldonk, A. van (Author) , Zonderhuis, B. (Author) , Javed, A.A. (Author) , Sterk, A. (Author) , Schoorlemmer, A. (Author) , Stam, A. (Author) , Nio, C.Y. (Author) , Alphen, E. van (Author) , Laarhoven, H.W.M. van (Author) , Veenendaal, H. van (Author) , Griffioen, I. (Author) , Rompen, I.F. (Author) , Klaase, J.M. (Author) , Los, M. (Author) , Marting, M.F.M.A. (Author) , Liem, M.S.L. (Author) , Peters, J. (Author) , Peters, L.J. (Author) , Garms, Linda (Author) , Walma, M. (Author) , Brada, L.H.J. (Author) , Seijbel, M. (Author) , Hildebrand, N.D. (Author) , Michiels, N. (Author) , Bax, R. (Author) , Dam, R.M. van (Author) , Achten, S. (Author) , Bouwense, S. (Author) , Augustinus, S. (Author) , Rötgerink, S. (Author) , Ravens, T.W. van (Author) , Nieuwenhuijs, V.B. (Author) , te Riele, W.W. (Author)
Format: Article (Journal)
Language:English
Published: February 19, 2025
In: BMC cancer
Year: 2025, Volume: 25, Pages: 1-12
ISSN:1471-2407
DOI:10.1186/s12885-025-13554-w
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-025-13554-w
Get full text
Author Notes:T.F. Stoop, L.W.F. Seelen, F.R. van ’t Land, A.C. van der Hout, J.C.M. Scheepens, M. Ali, A.M. Stiggelbout, B.M. van der Kolk, B.A. Bonsing, D.J. Lips, D.J.A. de Groot, E. van Veldhuisen, E.D. Kerver, E.R. Manusama, F. Daams, G. Kazemier, G.A. Cirkel, G. van Tienhoven, G.A. Patijn, H.N. Lelieveld-Rier, I.H. de Hingh, I.E.G. van Hellemond, J.H. Wijsman, J.I. Erdmann, J.S.D. Mieog, J. de Vos-Geelen, J.W.B. de Groot, K.R.D. Lutchman, L.J. Mekenkamp, L.W. Kranenburg, L.P.M. Beuk, M. W. Nijkamp, M. den Dulk, M.B. Polée, M.Y.V. Homs, M.L. Wumkes, M.W.J. Stommel, O.R. Busch, R.F. de Wilde, R.T. Theijse, S.A.C. Luelmo, S. Festen, T.L. Bollen, U.P. Neumann, V.E. de Meijer, W.A. Draaisma, B. Groot Koerkamp, I.Q. Molenaar, C.L. Wolfgang, M. Del Chiaro, M.G.H. Katz, T. Hackert, J.A.C. Rietjens, J.W. Wilmink, H.C. van Santvoort, C.H.J. van Eijck, M.G. Besselink and for the Dutch Pancreatic Cancer Group
Description
Summary:The introduction of (m)FOLFIRINOX and gemcitabine-nab-paclitaxel has changed the perspective for patients with locally advanced pancreatic cancer (LAPC). Consequently, in experienced centres 23% of patients with LAPC undergo a resection with 5-year overall survival (OS) rates of up to 25%. In the Netherlands, the nationwide resection rate for LAPC remains low at 8%. The PREOPANC-4 program aims for a nationwide implementation of the international multidisciplinary best-practice to improve patient outcome.
Item Description:the Dutch Pancreatic Cancer Group: A. Bruynzeel, A. Vlijm, A. van Asseldonk, B. Zonderhuis, A.A. Javed, A. Sterk, A. Schoorlemmer, A. Stam, C.Y. Nio, E. van Alphen, H.W.M. van Laarhoven, H. van Veenendaal, I. Griffioen, I.F. Rompen, J.M. Klaase, M. Los, M.F.M.A. Marting, M.S.L. Liem, J. Peters, L.J. Peters, Linda Garms, M. Walma, L.H.J. Brada, M. Seijbel, N.D. Hildebrand, N. Michiels, R. Bax, R.M. van Dam, S. Achten, S. Bouwense, S. Augustinus, S. Rötgerink, T.W. van Ravens, V.B. Nieuwenhuijs, W.W. te Riele
Online veröffentlicht am 19. Februar 2015
Gesehen am 09.12.2025
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-025-13554-w